skip to main content

Atopic Eczema — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

HardDermatopharmacologyAtopic EczemaSCE Dermatology

A 30-year-old man with severe atopic eczema has been tried on Dupilumab, Baricitinib and Upadacitinib without adequate response. His dermatologist considers Tralokinumab. What is the rationale for trying Tralokinumab after failure of Dupilumab?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Tralokinumab selectively blocks IL-13 only (not IL-4), which may provide a different clinical benefit in patients where IL-13 is the predominant driver; the mechanisms are not identical

Although Dupilumab and Tralokinumab both address type 2 inflammation, their targets differ: Dupilumab blocks IL-4Rα (inhibiting both IL-4 and IL-13), while Tralokinumab directly neutralises IL-13 only. In patients where IL-13 is the predominant pathogenic cytokine, selective IL-13 blockade may provide benefit even after IL-4Rα blockade fails. Additionally, the direct neutralisation of IL-13 by Tralokinumab may have different pharmacodynamic effects than receptor blockade. Clinical experience suggests some patients respond to one agent but not the other, supporting the concept that individual patients may have different cytokine-driven disease profiles. Sequential use is reasonable in refractory disease.

Reference: NICE TA910 Tralokinumab; BAD